

UC Irvine

UC Irvine Previously Published Works

Title

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer

Permalink

<https://escholarship.org/uc/item/2c4197vm>

Authors

Gupta, Rohan
Cristea, Mihaela
Frankel, Paul
et al.

Publication Date

2019

DOI

10.1016/j.ctarc.2019.100155

Peer reviewed



Published in final edited form as:

Cancer Treat Res Commun. 2019 ; 21: 100155. doi:10.1016/j.ctarc.2019.100155.

Randomized Trial of Oral Cyclophosphamide versus Oral Cyclophosphamide with Celecoxib for Recurrent Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Gupta Rohan¹, Cristea Mihaela, MD¹, Frankel Paul, PhD², Ruel Christopher², Chen Chen³, Wang Yingyu³, Morgan Robert, MD¹, Leong Lucille, MD¹, Chow Warren, MD¹, Koczywas Marianna, MD¹, Koehler Steve, MD¹, Lim Dean, MD¹, Luu Thehang, MD¹, Martel Cynthia, MD¹, McNamara Mark, MD¹, Somlo George, MD¹, Twardowski Przemyslaw, MD¹, Yen Yun, MD¹, Idorenyi Amanam, MD¹, Raechelle Tinsley⁴, Carroll Mary⁴, Chung Vincent, MD¹

¹Department of Medical Oncology & Therapeutics Research, City of Hope National Cancer Center, Duarte, CA

²Information Sciences, City of Hope National Cancer Center, Duarte, CA

³Clinical Informatics, City of Hope National Cancer Center, Duarte, CA

⁴Clinical Trial Office, City of Hope National Cancer Center, Duarte, CA

Abstract

Background: Oral metronomic chemotherapy, which has low toxicity, has demonstrated promising anti-tumor and anti-angiogenic properties that may lead to prolonged progression-free survival and improved response rates in patients with recurrent epithelial ovarian cancer (EOC). These effects may be enhanced by the co-administration of anti-angiogenic agents.

Methods: We conducted a randomized phase II clinical trial to evaluate the therapeutic benefit of oral metronomic cyclophosphamide (CTX) alone and with the anti-angiogenic drug celecoxib in patients with gynecological malignancies. 52 patients were randomly assigned to two treatment arms: 50 mg oral CTX daily alone (Arm A) or with 400 mg celecoxib twice daily (Arm B). The primary endpoint was response rate. Secondary endpoints included toxicity, time to treatment failure, and overall survival.

Results: In Arm A (n=26), 3 patients (12%) had stable disease > 6 months and 1 (4%) had a partial response. In Arm B, 5 (19%) had stable disease > 6 months and 1 patient (4%) had a partial response. There were no significant between-group differences in overall survival (9.69 months [95% CI 3.84–13.18] vs. 12.55 months [6.67–17.61]) or in median time to treatment failure (1.84

Corresponding Author: Vincent Chung, MD, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Director Phase I Program, 1500 East Duarte Road, Duarte, CA, 91010, Phone: 626-256-4673, VChung@coh.org.

Disclosure: No Conflict of Interest to be disclosed

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

months [1.68–2.76] vs. 1.92 months [1.64–5.22]). The most common adverse events were nausea, vomiting, and abdominal pain.

Conclusions: Oral metronomic CTX has activity with no major toxicities in heavily pretreated recurrent gynecological cancers and may be considered in patients with indolent disease. We did not observe any additional benefit of celecoxib treatment, though this may be due to small sample sizes.

Keywords

Oral Cyclophosphamide; Celecoxib; Ovarian Cancer

Introduction

In the United States, epithelial ovarian cancer (EOC) is the fifth most common cancer in women and the leading cause of death amongst gynecological malignancies. It is estimated that 22,530 women will be diagnosed in 2019 and 13,980 women will die from the disease[1]. The primary treatment for EOC consists of aggressive surgical staging and cytoreduction, followed by systemic chemotherapy in virtually all patients. Despite aggressive and often highly toxic[2] therapy, over 75% of patients develop and often eventually succumb to recurrent disease[3].

Cyclophosphamide (CTX) is a cell-cycle non-specific alkylating agent with activity against many solid tumors [4]. CTX plus cisplatin was a standard chemotherapy regimen in ovarian cancer[5] in the early 1990s, before being replaced by cisplatin plus paclitaxel in the mid-1990s and carboplatin plus paclitaxel around 2000.

To minimize side effects while maintaining potency, alternative treatment schedules have been explored. Metronomic dosing of standard chemotherapeutic agents, which generally consists of chronic, equally spaced, low doses, has been shown to target the microvasculature in animal models, resulting in significant antitumor activity with tolerable side effects. Tumor growth and metastasis are dependent upon vascularization[6–8], which results from a cascade of molecular and cellular events initiated by the release of angiogenic growth factors[7, 9, 10]. Pharmacological targeting of the microvasculature has demonstrated anti-tumor activity in several solid tumors [11–13]. Metronomic dosing of CTX has demonstrated clinical benefits in ovarian cancer, with stabilization of disease reported in several case reports and retrospective studies[14–16]. A retrospective Italian study of 54 patients showed an objective response rate of 20.4% with 50 mg oral CTX daily[16], with a majority of responses (72%) observed in platinum-sensitive patients (n=34). Watanabe et al. planned a prospective feasibility study of 50 mg oral CTX twice a day in patients with recurrent EOC. In the heavily pretreated population, 9/14 patients had either a partial response (PR) or stable disease (SD)[17]. However, the study was stopped early due to slow accrual.

Cyclooxygenase-2 (COX-2) is an enzyme involved in the conversion of arachidonic acid to prostaglandins, and its expression is increased in inflammatory states and malignancies [18–23]. Selective inhibitors of COX-2 have been shown to decrease angiogenesis, suggesting

the potential utility of these agents in oncology[24, 25]. Treatment with selective COX-2 inhibitors induces apoptosis in a variety of cancer cells, including colon, stomach, and prostate tumor cells [26–29]. One mechanism for the pro-apoptotic activity of COX-2 inhibitors is the down regulation of BCL-2, which in turn reduces vascular endothelial cell survival[27]. Celecoxib, a potent and selective COX-2 inhibitor, also induces apoptosis by blocking AKT activation, independent of BCL2[30], which is a critical signaling pathway for vascular endothelial cell survival [31–34].

Preclinical studies have consistently demonstrated that combinations of anti-angiogenic and chemotherapeutic compounds have synergistic anti-tumor activity [35, 36]. A recent meta-analysis [37] showed that in patients newly diagnosed with EOC, the addition of angiogenesis inhibitors to standard chemotherapy can lead to improved PFS; however, improved overall survival (OS) was observed only in patients at high risk for progression (i.e., with FIGO stage IV disease or stage III disease and > 1.0 cm of residual disease after debulking surgery). In patients with recurrent EOC, combination treatment with angiogenesis inhibitors and chemotherapy demonstrated improvements in PFS and OS, whereas the administration of angiogenesis inhibitors alone for maintenance therapy showed no significant improvement for either PFS or OS. The combination dose of celecoxib 400 mg oral twice a day and metronomic CTX oral 50 mg daily was chosen because safety and tolerability of this regimen has been demonstrated in prior early phase clinical trials in advanced malignancies[38{Twardowski, 2005 #63, 39, 40}].

Considering the safety, tolerability, and anti-angiogenic properties of both celecoxib and metronomic dosing of CTX, we conducted this phase II clinical trial to test their combined activity and tolerability in patients with recurrent gynecological cancers, including EOC fallopian tube and primary peritoneal cancers.

Materials and Methods

Study Design and Procedures

This was a single center, open-label, randomized phase II study of metronomic oral CTX with or without celecoxib in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients were randomly assigned at a ratio of one to one to receive either 50 mg oral CTX daily alone (Arm A) or in combination with 400 mg oral celecoxib twice per day (Arm B). One treatment cycle was defined as 28 days, and treatment continued until disease progression, unacceptable toxicity, or treatment delays for more than 3 weeks. Toxicities were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v2.0). The primary objective of the study was to evaluate the response rate, as assessed by Response Evaluation Criteria in Solid Tumors (RECIST version 1.0). Secondary objectives included evaluation of OS, correlation of PFS with cancer antigen 125 (CA 125) levels in the blood, and the safety profile of CTX in combination with celecoxib.

The study was approved by the Institutional Review board (IRB) of City of Hope and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Written informed consent was obtained from all patients prior to inclusion in the study

according to institutional guidelines. The protocol was monitored by the City of Hope Data Safety and Monitoring Committee per the institutional guidelines.

Patients

Patients were eligible if they were 18 years or older and had histologically confirmed recurrent or residual epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patient's disease was then sub classified as platinum refractory or resistant cancer. Patients with platinum free interval (PFI) of 6 months or longer were considered to have platinum sensitive disease whereas those with PFI of less than 6 months were considered to have platinum resistant disease. Patients who experience disease progression during first-line platinum therapy were considered to have platinum refractory disease.

There was no limit on prior lines of therapy. Patients with biochemical relapse (defined by Gynecologic Oncology Group criteria as rise in CA 125 with no radiographic evidence of disease) and no measurable disease and patients with stable brain metastases were eligible. Other key inclusion criteria included: serum creatinine < 1.5 mg/dL, adequate bone marrow function as evidenced by an absolute neutrophil count > $1.5 \times 10^9/L$ and a platelet count > $100 \times 10^9/L$, Karnofsky performance status of 60–100, and life expectancy of at least 3 months.

Patients were excluded from the study if they had radiotherapy or chemotherapy within 3 weeks prior to the anticipated first day of dosing, unstable or severe medical conditions, active infections, bleeding peptic ulcer within the last 3 months, history of allergic reactions to NSAIDs or sulfa drugs, pregnancy, or significant cardiovascular disease.

Assessment of Response and Toxicity

Measurable lesions and response assessments were defined according to RECIST (version 1.0). Baseline CA 125 was measured at 3 weeks prior to initiation of study. For response assessment, tumor maker CA 125 was checked each cycle (every 4 weeks) and tumor measurements were done, via imaging, every 2 cycles (every 8 weeks). OS was defined as the time from registration to time of death due to any cause. PFS was defined as the time from registration to the first observation of disease progression or death. Failure free survival was defined as the time from registration to the first observation of discontinuation of treatment. Although the original protocol plan was to report on PFS, we report on failure-free survival due to follow-up limitations on patients who stopped therapy for reasons other than progression such as toxicities and patient choice (n=5). Treatment failure was defined as either discontinuation of therapy, disease progression, or death due to any cause, and failure-free survival was the time to that event.

Statistical Analysis

The analysis of each arm of this randomized pilot trial was conducted independently. Responders included patients whose best overall response was a PR, a complete response (CR), or SD. Simon's two-stage minimax design was used for each arm. We assumed that a true response rate > 20% would warrant further study for an arm, while a true response rate < 5% would not warrant further study. Using this design, the probability of

correctly declaring that an arm with a true response rate of 20% warranted further study was 0.80 (power). The probability of falsely declaring that an arm with only a 5% true response rate warrants further study was 0.05 (alpha). For each arm, in the first stage of accrual, 13 patients were enrolled and assessed. If no responses were observed, accrual was to be stopped with the conclusion that the regimen was not promising for further study. Provided that one or more responses were observed in the first 13 evaluable patients, 14 additional evaluable patients were accrued. Responses in 4 or more of the 27 patients would be considered evidence that the regimen warranted further study. Exact 95% confidence intervals calculated for response rates, time to treatment failure, duration of response, and survival were estimated using the product limit method of Kaplan-Meier.

Results

Study Population

Patient characteristics are shown in Table 1. The median age was 61 years (range 27–80), and the median Karnofsky performance status score was 90 (range 60–100). 83% of the patients had prior surgery, and 10% had prior radiation therapy. The most common histology was papillary serous carcinoma, present in 77% of the patients. 88% of the patients had primary malignancies of the ovaries, whereas others tumor sites were peritoneum (2%), fallopian tube (2%), subcutaneous soft tissues (4%), and female genital tract (4%). 60% of the patients received 4 or more lines of therapy prior to enrollment in the study, and 58% had platinum-resistant disease at the time of enrollment.

Efficacy

The swimmers plot in Figure 1 depicts when patients responded, as well as when and why patients came off of treatment. Best response data are summarized in Table 2. In Arm A, 3 patients (12%) had SD > 6 months, and 1 patient (4%) had a PR. In Arm B, 5 patients (19%) had SD > 6 months, and 1 patient (4%) had a PR. We found that 2 of 7 patients with SD in Arm A were progression-free for > 6 months, and 3 of 8 patients with SD in Arm B were progression-free for > 6 months. One patient in Arm B had prolonged SD and remained on the treatment for 15 months. Across the two arms, patients with higher than median baseline CA 125 levels were on treatment for a shorter duration than patients with lower than median baseline CA 125 levels (1.87 months vs. 2.93 months, $p=0.02$), as shown in Figure 2a. Additionally, reduced CA125 levels after 1 month of treatment correlated with longer treatment durations ($p=0.01$), as shown in Figure 2b.

Median OS was not significantly different between groups: 9.69 months (95% CI 3.84–13.18) in Arm A compared to 12.55 months (95% CI 6.67–17.61) in Arm B (Figure 3). Additionally, time to treatment failure was not significantly different between groups: 1.84 months (95% CI 1.68–2.76) in Arm A compared to 1.92 months (95% CI 1.64–5.22) in Arm B (Figure 4). Progression free survival was not significantly different between groups: 1.84 months (95% CI 1.17–3.68) in Arm A compared to 2.02 months (95% CI 1.68–5.42) in Arm B (Supplemental Figure 1). 48 of 52 patients (92%) discontinued the study due to progressive disease (Figure 1). One patient was involuntarily withdrawn due to early death, two patients discontinued due to patient/MD decision (one had to undergo surgery), and one

patient came off treatment at 21 days due to toxicity but continued on single-agent CTX (off protocol) for 2 years (Figure 1).

Safety

Treatment-related adverse events are listed in Table 3. The most common grade 2 toxicities in Arm A were fatigue (27%), abdominal pain (23%), nausea/vomiting (27%), diarrhea (19%), hyperglycemia (15%), hypoalbuminemia (12%), anemia (15%), and sensory neuropathy (4%). The most common grade 2 toxicities in Arm B were abdominal pain (35%), nausea/vomiting (31%), fatigue (23%), and anemia (15%). Treatment was well-tolerated overall with minimal grade 3–4 toxicities. In Arm A, 1 patient had grade 4 hypercalcemia, and in Arm B, 1 patient had grade 4 anorexia. Grade 3 toxicities included fatigue (8% in Arm A and 4% in Arm B), anemia (8% in Arm B), dyspepsia (4% in Arm B), infection (4% in Arm A), muscle weakness (4% in both arms), sensory neuropathy (4% in Arm A), low albumin (4% in Arm B), dyspnea (4% in Arm A), and rash (4% in Arm B).

Discussion

Metronomic dosing has been explored as a potential way to minimize the toxicity of chemotherapies while maintaining efficacy. Our trial aimed to analyze the activity of oral metronomic CTX alone and in combination with celecoxib. We observed a slightly longer OS in the combination arm (12.6 vs. 9.7 months, Figure 3), however, this was not statistically significant. In this small trial, our data suggests that the combination of metronomic CTX and celecoxib did not perform better than single agent CTX. It is possible that our study was underpowered to detect a small but statistically significant difference between the treatment arms. Also, we enrolled a heterogeneous population of heavily pre-treated ovarian cancer patients with a high frequency of chemo-resistant disease unlikely to respond to another line of chemotherapy. Despite this, we still observed clinical and biochemical responses. Our trial showed that 10 patients (19%) experienced clinical benefit upon treatment with CTX alone or in combination with celecoxib (4% had a PR and 15% had SD > 6 months). Best response to treatment was observed in a patient treated in Arm B, who had SD for 15 months.

Several factors may contribute to treatment responses, and we endeavored to identify predictive factors for response common among treatment responders. Subgroup analysis showed that patients with baseline CA 125 levels below the median CA 125 for all patients (387.5 mg/dL) had longer treatment durations than those with CA 125 levels above the median. In addition, there was a statistically significant correlation between decrease in CA 125 levels after 1 month of treatment and the median duration of treatment ($p=0.01$). These correlations are concordant with previously published data showing improved survival in patients whose CA125 levels were reduced in response to treatment[41] and suggest that patients with low-burden disease may be better suited for this treatment approach than patients with more aggressive disease.

Unresectable ovarian cancer remains incurable and chemotherapy is palliative to help control disease and extend survival. Due to toxicities of chemotherapy, maintenance therapy has become a more common strategy for many cancers to control disease while maintaining

quality of life. Our trial demonstrated activity with metronomic dosing of CTX and was well tolerated in patients with indolent disease.. Even though we may not see added benefit of celecoxib, anti-angiogenesis has shown promising results in ovarian cancer. Novel clinical trials incorporating metronomic cyclophosphamide and check point inhibitors[42] or other immunotherapy agents are ongoing and may prove useful in ovarian cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Funding:

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572.

References

1. Siegel RL, Miller KD, and Jemal A, Cancer statistics, 2018. CA: a cancer journal for clinicians, 2018. 68(1): p. 7–30. [PubMed: 29313949]
2. Folkman J, Tumor angiogenesis: therapeutic implications. New england journal of medicine, 1971. 285(21): p. 1182–1186.
3. Du Bois A, et al. , Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 2009. 115(6): p. 1234–1244. [PubMed: 19189349]
4. O’Shaughnessy JA, Oral alkylating agents for breast cancer therapy. Drugs, 1999. 58(3): p. 1–9.
5. McGuire WP, et al. , Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 1996. 334(1): p. 1–6.
6. Simon SM and Schindler M, Cell biological mechanisms of multidrug resistance in tumors. Proceedings of the National Academy of Sciences, 1994. 91(9): p. 3497–3504.
7. Lyden D, et al. , Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature, 1999. 401(6754): p. 670. [PubMed: 10537105]
8. Hanahan D and Folkman J, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. cell, 1996. 86(3): p. 353–364. [PubMed: 8756718]
9. Kerbel RS, Tumor angiogenesis: past, present and the near future. Carcinogenesis, 2000. 21(3): p. 505–515. [PubMed: 10688871]
10. Kandel J, et al. , Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell, 1991. 66(6): p. 1095–1104. [PubMed: 1717155]
11. Zetter BR, Angiogenesis and tumor metastasis. Annual review of medicine, 1998. 49(1): p. 407–424.
12. Lannutti BJ, et al. , Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer research, 1997. 57(23): p. 5277–5280. [PubMed: 9393749]
13. O’Reilly MS, et al. , Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. cell, 1997. 88(2): p. 277–285. [PubMed: 9008168]
14. Perroud HA, et al. , Clinical response in patients with ovarian cancer treated with metronomic chemotherapy. ecancermedicalscience, 2017. 11.
15. Sánchez-Muñoz A, et al. , Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology, 2010. 79(1–2): p. 98–104. [PubMed: 21079407]
16. Ferrandina G, et al. , Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study. BMC cancer, 2014. 14(1): p. 947. [PubMed: 25495785]

17. Watanabe Y, et al. , Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. *International journal of clinical oncology*, 2010. 15(5): p. 468–471. [PubMed: 20480200]
18. Eberhart CE, et al. , Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology*, 1994. 107(4): p. 1183–1188. [PubMed: 7926468]
19. Koga H, et al. , Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. *Hepatology*, 1999. 29(3): p. 688–696. [PubMed: 10051469]
20. Tucker ON, et al. , Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. *Cancer research*, 1999. 59(5): p. 987–990. [PubMed: 10070951]
21. Hwang D, et al. , Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. *JNCI: Journal of the National Cancer Institute*, 1998. 90(6): p. 455–460. [PubMed: 9521170]
22. Hida T, et al. , Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. *Cancer research*, 1998. 58(17): p. 3761–3764. [PubMed: 9731479]
23. DeNardo DG, Andreu P, and Coussens LM, Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. *Cancer and Metastasis Reviews*, 2010. 29(2): p. 309–316. [PubMed: 20405169]
24. Masferrer JL, et al. , Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. *Cancer research*, 2000. 60(5): p. 1306–1311. [PubMed: 10728691]
25. Masferrer JL, Koki A, and Seibert K, COX-2 Inhibitors: A New Class of Antiangiogenic Agents. *Annals of the New York Academy of Sciences*, 1999. 889(1): p. 84–86. [PubMed: 10668485]
26. Erickson BA, et al. , The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. *Journal of Surgical Research*, 1999. 81(1): p. 101–107.
27. Sheng H, et al. , Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. *Cancer research*, 1998. 58(2): p. 362–366. [PubMed: 9443418]
28. Sawaoka H, et al. , Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 1998. 274(6): p. G1061–G1067.
29. Liu X-H, et al. , NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. *Cancer research*, 1998. 58(19): p. 4245–4249. [PubMed: 9766645]
30. Hsu A-L, et al. , The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. *Journal of Biological Chemistry*, 2000. 275(15): p. 11397–11403.
31. Papapetropoulos A, et al. , Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. *Journal of Biological Chemistry*, 2000. 275(13): p. 9102–9105.
32. Dimmeler S and Zeiher AM, Akt takes center stage in angiogenesis signaling, 2000, *Am Heart Assoc*.
33. Jiang B-H, et al. , Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. *Proceedings of the National Academy of Sciences*, 2000. 97(4): p. 1749–1753.
34. Hermann C, et al. , Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. *Arteriosclerosis, thrombosis, and vascular biology*, 2000. 20(2): p. 402–409.
35. Teicher BA, et al. , Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. *Breast cancer research and treatment*, 1995. 36(2): p. 227–236. [PubMed: 8534870]
36. Kato T, et al. , Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. *Cancer research*, 1994. 54(19): p. 5143–5147. [PubMed: 7522956]
37. Wang H, et al. , Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. *International Journal of Gynecological Cancer*, 2018.

38. Perroud HA, et al. , Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. *Future Oncology*, 2013. 9(3): p. 451–462. [PubMed: 23469980]
39. El Bary NA, et al. , A phase II study of high-dose celecoxib and metronomic'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma. *Hematology/oncology and stem cell therapy*, 2010. 3(1): p. 13–17. [PubMed: 20231809]
40. Twardowski P, et al. , Phase I trial of oral cyclophosphamide in combination with celecoxib in patients with advanced malignancies. *Journal of Clinical Oncology*, 2005. 23(16_suppl): p. 3196–3196.
41. Gupta D and Lis CG, Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. *Journal of ovarian research*, 2009. 2(1): p. 13. [PubMed: 19818123]
42. Zsiros E FP, Akers SN, et al., A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, Fallopian tube or primary peritoneal cancer.. Presented at: 2019 Annual Meeting of the Society of Gynecologic Cancer, 2019. Honolulu, Hawaii.




Figure 1.
Summary of patient responses.




Figure 2. Correlation of (a) baseline and (b) change in CA 125 with duration of treatment.




Figure 3. Overall survival (OS) of patients in treatment arms A and B.




Figure 4. Time to treatment failure (TTF) of patients in treatment groups A and B.

Table 1.

Baseline characteristics of study participants.

ARM DESCRIPTIONS:			
Arm A: 50 mg oral cyclophosphamide daily			
Arm B: 50 mg oral cyclophosphamide daily + 400 mg oral celecoxib twice daily			
	Arm A	Arm B	All Patients
Number of eligible patients:	26	26	52
Median age (years):	60 (27–79)	61 (48–80)	61 (27–80)
Median Karnofsky performance status [*] :	90 (70–100)	90 (60–100)	90 (60–100)
Prior treatments:			
Radiation	2 (8%)	3 (12%)	5 (10%)
Chemotherapy	26 (100%)	26 (100%)	52 (100%)
Surgery ^{**}	21 (81%)	22(85%)	43 (83%)
Histology:			
Adenocarcinoma, not otherwise specified	2 (8%)	2 (8%)	4 (8%)
Clear cell adenocarcinoma	0 (0%)	1 (4%)	1 (2%)
Endometrioid adenocarcinoma	4 (15%)	1 (4%)	5 (10%)
Malignant Mullerian mixed tumor Carcinosarcoma	1 (4%)	0 (0%)	1 (2%)
Mixed adenocarcinoma	1 (4%)	0 (0%)	1 (2%)
Serous adenocarcinoma	18 (69%)	22 (85%)	40 (77%)
Site of primary disease:			
Fallopian tube	1 (4%)	0 (0%)	1 (2%)
Female genital tract	1 (4%)	1 (4%)	2 (4%)
Ovary	22 (85%)	25 (96%)	47 (90%)
Peritoneum	2 (8%)	0 (0%)	2 (4%)
Line of therapy prior to enrollment:			
Median (range)	3.5 (1–12)	4 (1–8)	4 (1–12)
1–3	13 (50%)	8 (31%)	21 (40%)
>=4	13 (50%)	18 (69%)	31 (60%)
Platinum resistant?			
Yes	14 (54%)	16 (62%)	30 (58%)
No	4 (15%)	4 (15%)	8 (15%)
Not Applicable	8 (31%)	6 (23%)	14 (27%)
Platinum refractory?			
Yes	1 (4%)	1 (4%)	2 (4%)
No	18 (69%)	18 (69%)	36 (69%)
Not Applicable	7 (27%)	7 (27%)	14 (27%)

* Missing performance status data for 6 patients.

** Excluding diagnostic procedures.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Best responses of study participants.

	Arm A	Arm B	All Patients
Number of patients	26	26	52
Best response			
Partial Remission	1 (4%)	1 (4%)	2 (4%)
Stable Disease	8 (31%)	9 (35%)	17 (32%)
Duration < 6 mo.	5 (19%)	4 (15%)	9 (17%)
Duration > 6 mo.	3 (12%)	5 (19%)	8 (15%)
Progression	16 (62%)	15 (58%)	31 (60%)
Response not applicable*	1 (4%)	1 (4%)	2 (4%)

* One patient in Arm A refused treatment after completing course 1. One patient in Arm B went off treatment due to toxicity after completing course 1.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3.

Treatment-related adverse events in study participants.

N* (%)	Arm A (n=26)			Arm B (n=26)		
	Grade 2	Grade 3	Grade 4	Grade 2	Grade 3	Grade 4
Anorexia	5(19%)	---	---	2(8%)	---	1(4%)
Calcium, serum-high	---	---	1(4%)	---	---	---
Fatigue	7(27%)	2(8%)	---	6(23%)	1(4%)	---
Hemoglobin	4(15%)	---	---	4(15%)	2(8%)	---
Lymphopenia	2(8%)	1(4%)	---	5(19%)	---	---
WBC	2(8%)	1(4%)	---	1(4%)	1(4%)	---
Heartburn/dyspepsia	---	---	---	1(4%)	1(4%)	---
Infection	1(4%)	1(4%)	---	1(4%)	---	---
Muscle weakness, generalized or specific area	1(4%)	1(4%)	---	---	1(4%)	---
Neuropathy: sensory	1(4%)	1(4%)	---	---	---	---
Phosphate, serum-low	1(4%)	1(4%)	---	1(4%)	---	---
Albumin, serum-low	3(12%)	---	---	---	1(4%)	---
Bicarbonate, serum-low	---	1(4%)	---	---	---	---
Dehydration	---	1(4%)	---	1(4%)	---	---
Dyspnea	---	1(4%)	---	1(4%)	---	---
Rash/desquamation	---	---	---	---	1(4%)	---
Sodium, serum-low	---	---	---	---	1(4%)	---
Pain	6(23%)	---	---	9(35%)	---	---
Nausea & Vomiting	7(27%)	---	---	8(31%)	---	---
Diarrhea	5(19%)	---	---	2(8%)	---	---
Hyperglycemia	4(15%)	---	---	1(4%)	---	---
Constipation	1(4%)	---	---	2(8%)	---	---
Edema	1(4%)	---	---	2(8%)	---	---

* At least one grade 3 or above or at least two grade 2 in any combination of arms.